[Breaking] Korea Union Pharmaceutical Postpones Listing Date for Capital Reduction and Paid-in Capital Increase New Shares to July 22, 2026
Korea Union Pharmaceutical has postponed the scheduled listing date for new shares from a capital reduction and two rounds of paid-in capital increases being co
![[Breaking] Korea Union Pharmaceutical Postpones Listing Date for Capital Reduction and Paid-in Capital Increase New Shares to July 22, 2026](https://media.cbcglobe.com/tenants/cbc00000-0000-4000-8000-000000000001/media/cbc/2026/06/579783/4e4da2bfb8f012b9/variants/hero.webp)
Korea Union Pharmaceutical has postponed the scheduled listing date for new shares from a capital reduction and two rounds of paid-in capital increases being conducted under its corporate rehabilitation proceedings to July 22, 2026.
According to a corrected disclosure filed by the company on the 8th, the change in the listing date was a measure resulting from delays in administrative procedures with the Korea Securities Depository. The originally scheduled listing date was July 15, 2026. The specific details of the changes and capital increases are as follows.
① Share Consolidation (Capital Reduction) Other details, including the capital reduction ratio, remain unchanged from the original plan. Under the consolidation, three common shares will be merged into one share for a total of 59,573,136 common shares. Upon completion of the capital reduction, the total number of issued shares will be 19,854,006, with a capital stock of 9,927,003,000 KRW.
② Conversion of Rehabilitation Claims into Equity (Third-Party allotment Paid-in Capital Increase) This is a debt-to-equity swap for debt repayment and involves no new cash contributions. A total of 51,660,308 common shares will be issued at 500 KRW per share, and the scheduled listing date has been changed to July 22 for the same reason.
③ Rehabilitation M&A (Third-Party allotment Paid-in Capital Increase) This is a capital increase for rehabilitation M&A with Bugwang Pharmaceutical as the allottee. A total of 60,000,000 common shares will be issued at 500 KRW per share to raise a total of 30 billion KRW. These funds will be used to improve the company's financial structure in accordance with the rehabilitation plan. The scheduled listing date for the new shares from this capital increase has also been postponed to July 22, 2026.
Korea Union Pharmaceutical stated, "The listing schedule may be subject to further changes depending on future decisions by the rehabilitation court and the progress of administrative procedures," adding, "We plan to make additional disclosures if any changes occur."
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.


![[Breaking] Daewoo Construction Wins 818.1 Billion Won Contract for New Mixed-Use Complex in Incheon Cheongna International Business District](https://media.cbcglobe.com/tenants/cbc00000-0000-4000-8000-000000000001/media/cbc/2026/06/579257/7871aedeeb446473/variants/hero.webp)
